Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: J Surg Oncol. 2013 Sep;108(4):10.1002/jso.23392. doi: 10.1002/jso.23392

Table II. Treatment characteristics of neoadjuvant FOLFIRINOX.

Treatment Characteristics
Treatment Cycles
Mean 5
1-3, n(%) 6 (29%)
4-6, n(%) 12 (57%)
≥7, n(%) 2 (10%)
Dose Reduction, n(%) 6 (29%)
Treatment Delays, n(%) 5 (24%)
Delay Duration, weeks
(mean)
1.5
Admission During Tx, n(%) 4 (19%)
Additional Treatment, n(%)
Chemotherapy 4 (19%)
SBRT 12 (57%)